EPIDEMIOLOGY AND MANAGEMENT OF OVARIAN CANCER BASED ON THE CLINICAL EXPERIENCE OF THE SOUTHERN REGION OF UKRAINE.

The aim of the study was to evaluate the clinical and epidemiological characteristics of the contingent of patients with RH on the example of the southern region of Ukraine. The research was carried out at the clinical bases of the Department of surgery № 4 with oncology course of the Odessa National Medical University. The standardized indicators of morbidity and mortality for 2007-2016 are analyzed. In addition, an analysis of the survival of 350 patients with stage III-IV in the period 2011-2015 was evaluated. The total one-and three-year survival (TS - total survival); disease free one-and three-year survival (DFS) - disease free survival; FFTF - freedom from treatment failure; event free survival (EFS) - event free survival were estimated. All patients were examined using conventional clinical and laboratory methods according to the standards of diagnosis and treatment of cancer patients, approved by orders of the Ministry of Health of Ukraine No. 140 dated 27.07.1998 and No. 554 dated 17.09.2007. The stage of the tumor process was determined according to the International Classification of TNM 6-th edition (2009). Patients have agreed to use individual clinical data for scientific purposes. The lifetime curves and the values of the surrogate variable were created by the Kaplan-Meyer method. Statistical analysis of the data was performed using the Statistica 10.0 (Dell StatSoft Inc., USA) package; It was established that during the analyzed period (2007-2016) in Odessa oblast there was a gradual decrease in mortality from RV from 5.5 cases per 100,000 population in 2007 to 3.8 in 2016. Dynamics of standardized indicators of morbidity and mortality from the RN shows a probable depopulation and on the effectiveness of the measures used in the region in the primary and secondary prevention of oncopathology. The overall survival of patients with severe forms of URN does not exceed 30 months (28.3±1.4 months). The use of HIPEC technology can increase the overall survival rate to 33.1±1.4 months, DFS to 17.2±1.6 months, FFTF to 17.0±1.6 months, EFS to 16.8±0,9 months, and PFS - up to 16,9±0,8 months.

[THE FEATURES OF THE COURSE OF INFECTIOUS MONONUKLEOSIS OF DIFFERENT ETIOLOGY IN CHILDREN].

Aim - to study the effect of different pathogens (EBV, CMV, HHV-6, and MIXT) on the severity of clinical-paraclinical manifestations of infectious mononucleosis in children. The clinical and laboratory study performed for 410 children aged from 10 months up to 12 years with infectious mononucleosis. The association of herpes viruses, mainly EBV, CMV and HHV type 6, takes part in the formation of the clinical picture of IM in (52,9%) of cases. The sole participation of EBV in the development of IM was observed only in (34,1%), CMV (9,02%) and HHV-6 in (3,17%) patients. The etiology of infectious mononucleosis in children affects the acuity, severity, and intensity of the clinical and paraclinical signs of the disease. Infectious mononucleosis VEB etiology is manifested by acute onset (79,5%), intoxication (70,5%), subfebrile and febrile fever up to 7 days (61,03%), lacunar tonsillitis (85,8%), hepatomegaly ( 88,2%), splenomegaly (63,8%), mostly moderate (81,7%) with lymphocytosis (62,9%) and monocytosis (20,5%). For CMV mononucleosis - acute onset (89,9%), severe course (29,8%), febrile and high fever for up to 7 (56,7%) or more days, neutrophilic leukocytosis (73,55) with atypical mononuclear cells (64,7%) and anemia (29,7%). Severe (33,3%), with prolonged high fever (50%), exanthema syndrome (33,3%), pharyngitis without tonsillitis (66,7%), leukocytosis (66,7%) with accelerated ESR (66,7%) and monocytosis (33,3%) are characteristic of HHV-6 infection. For MIXT - acute onset (78,3%), intoxication (79,7%), lacunar tonsillitis (92,9%), hepatomegaly (84,1%) and splenomegaly (67%), low-grade and febrile fever from 3- x (27,1%) up to 7 days (35,05%), lymphocytosis (55,3%) with neutropenia (57,4%), atypical mononuclear cells (48,2%) and hypochromic anemia (17,29 %).